STRENGTH
July 6, 2024DAL OUTCOMES
July 6, 2024STRENGTH
July 6, 2024DAL OUTCOMES
July 6, 2024STRENGTH
July 6, 2024DAL OUTCOMES
July 6, 2024The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
Read Study